3,883
edits
Changes
B-ALL Tables: Prognostic Genomic Abnormalities and Recurrent Gene Fusions (view source)
Revision as of 10:50, 26 July 2021
, 10:50, 26 July 2021Jennelleh moved page B-ALL table to B-ALL Tables: Prognostic Genomic Abnormalities and Recurrent Gene Fusions without leaving a redirect: Final name
'''Table 1 - Gene fusions reported in Ph-like B-ALL and other new B-ALL molecular subtypes (Literature Review)'''. Table derived from Akkari et al., 2020 [PMID 32302940] with permission from Cancer Genetics.
'''Table 1 - Prevalence and prognosis of B-ALL genomic abnormalities in the pediatric and adult population for all categories reported to date.''' Of the Ph-like category, only CRLF2 and ABL1-class rearrangements are indicated. Table derived from Akkari et al., 2020 [PMID 32302940] with permission from Cancer Genetics. All percentages are approximate.
{| class="wikitable"
|
| colspan="2" |'''Percentage of B-ALL Cases'''
|
|-
|'''Genomic abnormality'''
|'''Pediatric'''
|'''Adult'''
|'''Prognosis'''
|-
|t(12;21)(p13;q22); [[ETV6]]-[[RUNX1]]*
|25%
|3%
|Favorable
|-
|Hyperdiploidy*
|25%
|5-7%
|Favorable
|-
|t(9;22)(q34;q11.2); [[BCR]]-[[ABL1]]*
|2-4%
|25-30%
|Poor (outcome may improve with TKI)
|-
|[[CRLF2]] (PAR1, Xp22.33/Yp11.2) (Ph-like)
|5%
|20%
|Poor
|-
|ABL-Class fusions (Ph-like)
|3-5%
|2-3%
|Poor (outcome may improve with TKI)
|-
|[[KMT2A Partner Genes|KMT2A]] (11q23) rearrangements*
|5%
|10%
|Poor
|-
|t(1;19)(q23;p13.3); [[TCF3]]-[[PBX1]]*
|5%
|3%
|Favorable
|-
|[[TCF3]] (19p13.3) rearrangements (excluding [[ZNF384]])
|>1%
|>1%
|Extremely Poor
|-
|Hypodiploidy*
|1-2%
|15%
|Poor
|-
|dic(9;12)(p13;p13)
|1%
|Rare
|Favorable
|-
|dic(9:20)(p13;q11)
|2%
|1%
|Favorable
|-
|t(4;14)(q35.2;q32); [[IGH-DUX4|IGH/DUX4]]
|5-9%
|5%
|Favorable
|-
|t(5;14)(q31.1;q32.1); [[IGH]]/[[IL3]]*
|1%
|1%
|Unknown
|-
|[[ZNF384]] (12p13.31) rearrangements
|1-5%
|2-7%
|Favorable
|-
|iAMP21 ([[RUNX1]])*
|2%
|Rare
|Poor
|-
|[[IKZF1]] deletions
|15-20%
|25-30%
|Poor except in combination with ERG del
|}
<nowiki>*</nowiki>indicates 2016 WHO entities including provisional categories.
'''Table 2 - Gene fusions reported in Ph-like B-ALL and other new B-ALL molecular subtypes (Literature Review)'''. Table derived from Akkari et al., 2020 [PMID 32302940] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Subtype'''
|'''Subtype'''
'''B-ALL'''
'''B-ALL'''
| rowspan="12" |'''''[[ABL1]]''''' (9q34)
| rowspan="12" |'''''[[ABL1]]'''''
(9q34)
|''[[CENPC1]]''
|''[[CENPC1]]''
|t(4;9)(q13;q34)
|t(4;9)(q13;q34)
|
|
|-
|-
| rowspan="3" |'''''[[ABL2]]''''' (1q25.2)
| rowspan="3" |'''''[[ABL2]]'''''
(1q25.2)
|''[[PAG1]]''
|''[[PAG1]]''
|t(1;8)(q25.2;q21.1)
|t(1;8)(q25.2;q21.1)
|
|
|-
|-
| rowspan="3" |'''''[[CSF1R]]''''' (5q32)
| rowspan="3" |'''''[[CSF1R]]'''''
(5q32)
|''[[MEF2D]]''
|''[[MEF2D]]''
|t(1;5)(q22;q32)
|t(1;5)(q22;q32)
|On the same chromosome arm; however, a simple deletion cannot cause the fusion due to the orientation of genes
|On the same chromosome arm; however, a simple deletion cannot cause the fusion due to the orientation of genes
|-
|-
| rowspan="22" |'''''[[JAK2]]''''' (9p24.1)
| rowspan="22" |'''''[[JAK2]]'''''
(9p24.1)
|''[[ATF7IP]]''
|''[[ATF7IP]]''
|-
|-
| rowspan="6" |'''''MEF2D-''rearranged B-ALL'''
| rowspan="6" |'''''MEF2D-''rearranged B-ALL'''
| rowspan="6" |'''''[[MEF2D]]''' (1q22)''
| rowspan="6" |'''''[[MEF2D]]'''''
(1q22)
|''[[BCL9]]''
|''[[BCL9]]''
|inv(1)(q21.2q22)
|inv(1)(q21.2q22)